NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, will participate in four investor conferences in September:
Live webcasts of the presentations at the Morgan Stanley and Cantor conferences can be accessed on the Investors page of the Company’s website at www.axsome.com. Replays of the webcasts will be available for approximately 30 days following each event.
About Axsome Therapeutics
Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians. For more information, please visit the Company’s website at www.axsome.com.
Investors:
Mark Jacobson
Chief Operating Officer
(212) 332-3243
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Darren Opland
Director, Corporate Communications
(929) 837-1065
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$89.16 |
| Daily Change: | 4.55 5.38 |
| Daily Volume: | 207,107 |
| Market Cap: | US$4.320B |
December 30, 2024 November 26, 2024 November 12, 2024 November 08, 2024 October 29, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
